Docoh
Loading...

IGMS IGM Biosciences

APP
Utility
Multimeric CD137/4-1BB Binding Molecules and Uses Thereof
16 Dec 21
This disclosure provides dimeric, pentameric, and hexameric CD137/4-1BB agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Bruce KEYT, Ramesh BALIGA, Beatrice Tien-Yi WANG
Filed: 17 Aug 21
APP
Utility
MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
9 Dec 21
This disclosure provides IgM- and IgA-derived binding molecules comprising binding polypeptides, e.g., receptor ectodomains, ligands, or receptor-binding fragments thereof, and the like, fused to multimerizing IgM or IgA constant regions.
Ramesh BALIGA, Paul HINTON, Dean NG, Bruce KEYT
Filed: 23 Oct 19
GRANT
Utility
Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
7 Dec 21
This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain.
Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
Filed: 7 Jan 20
APP
Utility
ANTI-PD-L1 Antibodies
3 Jun 21
Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
Bruce KEYT, Leonard George PRESTA, Ramesh BALIGA
Filed: 10 Feb 21
APP
Utility
Modified Human Igm Constant Regions for Modulation of Complement-dependent Cytolysis Effector Function
20 May 21
The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the Cμ3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.
Ramesh Baliga, Dean Ng
Filed: 6 Apr 18
GRANT
Utility
Modified J-chain
13 Apr 21
The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
Filed: 27 Feb 20
APP
Utility
IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
25 Mar 21
This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.
Ramesh BALIGA, Bruce KEYT, Dean NG
Filed: 3 Dec 20
GRANT
Utility
Anti-PD-L1 antibodies
23 Mar 21
Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
Bruce Keyt, Leonard George Presta, Ramesh Baliga
Filed: 9 May 17
APP
Utility
Tumor Necrosis Factor (TNF) Superfamily Receptor Binding Molecules and Uses Thereof
18 Feb 21
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Beatrice WANG, Max Allen SCHWARZER, Bruce Alan KEYT, Ramesh BALIGA
Filed: 28 Apr 20
APP
Utility
CD20 Binding Molecules and Uses Thereof
4 Feb 21
This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
Filed: 24 Jul 20
GRANT
Utility
IgM Fc and J-chain mutations that affect IgM serum half-life
26 Jan 21
This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.
Ramesh Baliga, Bruce Keyt, Dean Ng
Filed: 23 Mar 20
APP
Utility
Multi-valent Hepatitis B Virus Antigen Binding Molecules and Uses Thereof
6 Jan 21
This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain.
Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
Filed: 18 Feb 20
APP
Utility
Use of a Multimeric ANTI-DR5 Binding Molecule In Combination with a Chemotherapeutic Agent for Treating Cancer
16 Dec 20
This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a chemotherapeutic agent, e.g., a type I topoisomerase inhibitor, a nucleoside analog, or a pro-apoptotic agent, e.g., a BCL-2 inhibitor.
Beatrice Tien-Yi WANG, Bruce Alan KEYT
Filed: 24 Feb 19
APP
Utility
Multi-valent Human Immunodeficiency Virus Antigen Binding Molecules and Uses Thereof
2 Dec 20
This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain.
Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
Filed: 6 Jan 20
GRANT
Utility
IgA multi-specific binding molecules
2 Nov 20
The present invention concerns IgA multi-specific binding molecules.
Bruce Keyt, Leonard George Presta, Fen Zhang, Stephen F. Carroll
Filed: 9 Feb 15
GRANT
Utility
Multimeric bispecific binding molecules specific for CD20 and CD3
28 Sep 20
This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
Filed: 3 Mar 16
APP
Utility
Binding Molecules with Modified J-chain
12 Aug 20
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Filed: 15 Jan 20
APP
Utility
IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
29 Jul 20
This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.
Ramesh BALIGA, Bruce KEYT, Dean NG
Filed: 22 Mar 20
GRANT
Utility
Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
22 Jun 20
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Alan Keyt, Ramesh Baliga
Filed: 19 Jan 16
APP
Utility
Modified J-chain
17 Jun 20
The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
Filed: 26 Feb 20
Patents are sorted by USPTO publication date, most recent first